S23 (Mastorin) Driada Medical EU

S23 (Mastorin) – Driada Medical EU

The product details S23, an investigational Selective Androgen Receptor Modulator (SARM).¹ S23 is highly potent and was originally studied as a potential male hormonal contraceptive due to its strong suppression of reproductive hormones.²

Note: S23 is one of the most potent and suppressive SARMs. It is an unapproved investigational drug banned by WADA (World Anti-Doping Agency) due to safety concerns, including liver injury and cardiovascular risks.

Mechanism and Bodybuilding Profile

S23 is noted for its high binding affinity to the androgen receptor, making it stronger than older SARMs like Andarine.³

• Extreme Anabolic Effects: S23 promotes muscle growth and bone density (anabolic effects).⁴ Animal studies showed a dose-dependent increase in lean body mass (LBM) and suppression of fat mass (FM).⁵

• Contraceptive Potential: S23 was primarily researched as a potential male hormonal contraceptive due to its ability to strongly and reversibly suppress Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).⁶

• Tissue Selectivity: It is designed to selectively maintain muscle mass while having a relatively less potent effect on androgenic tissues like the prostate.⁷

Usage and Dosage Guidelines (Common Illicit Use)

• Dosage Range: Due to its potency and strong suppression, doses are typically kept low. Anecdotal illicit doses often range from 10 mg to 30 mg per day. The product is $10 text/text$.

• Frequency: Because its half-life is relatively short (around 12 hours), users often split the daily dose into two administrations to maintain stable blood levels.

• Cycle Duration: Cycles are generally kept short (6–8 weeks) due to the strong suppression and potential for severe side effects.

Side Effects and Risks

S23 is considered a harsh SARM with risks similar to those of traditional potent steroids.

• Severe HPTA Suppression (Major Risk): S23 causes profound and rapid suppression of natural testosterone and fertility (LH and FSH).⁸

  • PCT Required: A very aggressive and extended Post-Cycle Therapy (PCT) using a combination of compounds (like HCG and SERMs) is mandatory after use.

• Hepatotoxicity: The FDA has warned that SARMs, including S23, are associated with risks of liver injury and acute liver failure.⁹

• Cardiovascular Strain: Preliminary research has connected SARMs to an increased risk of heart attack or stroke and negative impacts on the lipid profile (lowering protective HDL cholesterol).¹⁰

• Other Side Effects: Side effects reported for SARMs generally include decreased testicular size, mood swings, sleep disturbances, and acne.¹¹

Frequently Asked Questions (FAQ)

1. What is the primary reason S23 was researched in clinical settings?

S23 was primarily investigated as a potential male hormonal contraceptive due to its highly potent and reversible suppression of sperm production and Luteinizing Hormone (LH).¹²

2. Is Post-Cycle Therapy (PCT) required after using S23?

Yes, PCT is mandatory and must be robust. S23 causes one of the most severe suppressions of natural testosterone and reproductive hormones among all SARMs.

3. What is the typical daily dosage range for S23?

Typical doses often range from 10 mg to 30 mg per day, usually split into two administrations.

4. What are the major known health risks associated with S23 and other SARMs?

Major known health risks include liver injury/failure, increased risk of heart attack or stroke, and severe suppression of the body’s natural hormone production.¹³